What Is Regenerative Medicine?

To understand what makes regenerative medicine different, it's worth looking at what traditional pain management actually does. The conventional pathway for a patient with chronic joint or tendon pain usually looks something like this: rest and ice, oral anti-inflammatories, physical therapy, cortisone injection, repeated cortisone injection, and eventually, when nothing else works, surgery.

Each of those steps has a role, but none of them actually repair damaged tissue. Rest and ice calm inflammation. Anti-inflammatories reduce pain signaling. Cortisone powerfully suppresses inflammation but can accelerate tissue breakdown over time, especially with repeated use. Surgery removes or replaces damaged structures but doesn't regenerate them.

Regenerative medicine takes a different approach. Rather than suppressing inflammation or masking pain signals, it delivers biological materials, growth factors, stem cells, signaling molecules, that cue the body to rebuild. The result, for the right candidates, is relief that comes from actual repair rather than from a chemical mask.

This distinction matters for a practical reason: patients who experience lasting improvement from regenerative medicine are usually experiencing it because the underlying tissue is healthier than it was before. That's a very different outcome than successful symptom control.

Stem cells are, at their simplest, cells that haven't yet decided what they're going to do when they grow up. They have two key properties: they can divide to produce more of themselves (self-renewal), and they can differentiate into specific tissue types as needed (potency).

In regenerative medicine, we're specifically interested in a class called mesenchymal stem cells, or MSCs. These are multipotent adult stem cells, meaning they can become several related cell types (bone, cartilage, muscle, tendon, ligament, connective tissue) but not any cell in the body. For musculoskeletal injury, that range is exactly what you want.

Historically, MSCs for clinical use were harvested from a patient's own bone marrow or fat tissue. This worked, but it had drawbacks: the harvest procedure itself was uncomfortable, and the yield of viable cells declined sharply with age. An 80-year-old patient has dramatically fewer and less potent stem cells in their tissue than a 30-year-old, which meant the treatment was often least effective for the patients who needed it most.

Umbilical cord-derived MSCs changed the math. Donated after healthy scheduled C-section deliveries with informed consent, umbilical cord tissue is rich in young, highly viable mesenchymal stem cells. It doesn't require a harvest procedure, and because these cells are immune-privileged, they don't require donor-recipient matching. For more on the specific products we use, see our pages on umbilical cord stem cells, Wharton's Jelly, and mesenchymal stem cells.

Platelet Rich Plasma therapy operates on a related but distinct principle. While stem cell therapy delivers regenerative cells themselves, PRP delivers the biological signals those cells use to communicate. Platelets, best known for their role in blood clotting, are also the body's primary delivery system for growth factors: small proteins that instruct tissue cells to divide, migrate, and repair.

When you draw a patient's blood and process it in a centrifuge, you can separate it into its component layers. The platelet-rich fraction contains a concentration of platelets many times higher than normal blood, modern systems routinely produce concentrations of 6x, 12x, or 18x baseline. Injecting that concentrate into damaged tissue delivers an overwhelming dose of growth factors exactly where repair is needed.

PRP has advantages that stem cell therapy doesn't: it's autologous (from the patient's own body, so there's no rejection risk), it's faster and less expensive, and it's been FDA-cleared through its preparation systems for over a decade. It has one key limitation: unlike stem cells, PRP provides signals but not new cells. For many conditions this is plenty. For more advanced conditions, stem cell therapy, or a combination, may be more appropriate.

Learn more on our PRP therapy page.

Regenerative medicine isn't appropriate for every condition or every patient. Good candidates generally share a few characteristics:

• A clearly identified tissue issue. Imaging, MRI or ultrasound, confirms a specific structural problem: cartilage wear, tendinopathy, partial ligament tear, etc.
• Conservative care has been tried. In most cases, the patient has already done some combination of physical therapy, activity modification, anti-inflammatories, or cortisone, and has seen limited or short-lived benefit.
• The damage isn't beyond biological repair. Regenerative medicine can support remodeling and partial repair, but it cannot reattach a fully ruptured tendon or rebuild a joint surface that is bone-on-bone.
• Reasonable general health. Certain medical conditions or medications can affect candidacy; these are reviewed carefully at consultation.
• A willingness to allow biological time. Regenerative medicine doesn't deliver instant relief. The repair process unfolds over weeks to months, patients who are expecting overnight results may be disappointed.

Honest candidacy conversations are a core part of our practice. If we don't believe regenerative medicine is likely to help your specific condition, we'll tell you, and help you understand what might.

The evidence base for regenerative medicine has grown dramatically in the past decade. PRP, in particular, now has extensive peer-reviewed research supporting its use in specific conditions, lateral epicondylitis (tennis elbow), knee osteoarthritis, patellar tendinopathy, and others. Multiple systematic reviews and meta-analyses have concluded that PRP can produce clinically meaningful improvements for appropriately selected patients.

The evidence for stem cell-based therapies is somewhat younger but actively expanding. A growing body of research suggests benefit in osteoarthritis, tendinopathies, and certain ligament injuries, with particularly promising results for moderate osteoarthritis of the knee and other large joints.

As with any field, research quality varies. Some studies are smaller and less rigorous than others, and it's important to distinguish high-quality evidence from promotional claims. Our practice stays current with the peer-reviewed literature and bases our protocol choices on the strongest available evidence.

Safety in regenerative medicine comes from two places: the quality of the products being used and the skill of the provider using them. Both matter.

On the product side, PRP is made from the patient's own blood using FDA-cleared preparation systems, and has been performed safely in clinical settings for well over a decade. Serious adverse events are rare, the most common side effect is temporary soreness at the injection site.

Stem cell products, including umbilical cord-derived MSCs and Wharton's Jelly, are processed in FDA-registered tissue banks under strict oversight. Every batch we use is screened to American Association of Tissue Banks (AATB) standards, including infectious disease panels, sterility testing, and cell viability verification. Because umbilical cord cells are immune-privileged, the risk of rejection is extremely low.

It's important to understand that the FDA does not evaluate umbilical cord or PRP products the same way it evaluates new pharmaceuticals. The preparation systems are FDA-cleared, and tissue products are regulated under FDA tissue banking rules, but the therapies themselves are not FDA-approved to cure or treat any specific disease. We're transparent about this because patients deserve to understand the regulatory context of their care.

The treatment experience itself is generally straightforward. Most procedures are outpatient, completed in 30 to 60 minutes, and require only local numbing where appropriate. Patients typically drive themselves home and return to light activity the same day. Mild soreness at the injection site for one to three days is normal.

Results develop gradually. In the first week or two, the body is responding to the injection, some patients notice little change yet, while others report early relief, particularly with treatments that include hyaluronic acid. Between weeks four and six, most patients begin to experience meaningful improvement in pain and function. Peak benefit typically occurs between two and six months post-treatment, with gains that often continue beyond.

Not every patient responds, and not every patient responds equally. We're straightforward about this upfront. For most conditions, we quote realistic expected response rates from published literature at consultation, so you can make a decision with honest numbers, not marketing promises.